Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial
暂无分享,去创建一个
S. Solomon | J. McMurray | K. Swedberg | J. Rouleau | M. Zile | M. Packer | B. Claggett | N. Bouabdallaoui | E. O'meara | M. Prescott | E. O’Meara
[1] L. Wallentin,et al. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. , 2017, Clinical chemistry.
[2] M. Pencina,et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. , 2012, European heart journal.
[3] R. Goldschmeding,et al. Circulating growth differentiation factor‐15 correlates with myocardial fibrosis in patients with non‐ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support , 2012, European journal of heart failure.
[4] L. Lind,et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. , 2013, Clinical chemistry.
[5] R. Prager,et al. GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. , 2016, Clinical chemistry.
[6] G. Brabant,et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.
[7] F. Tacke,et al. Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsis , 2017, Disease markers.
[8] J. Cohn,et al. Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure: Relation to Disease Severity and Prognosis in the Valsartan Heart Failure Trial , 2010, Circulation.
[9] Andrew D. Johnson,et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. , 2012, Clinical chemistry.
[10] B. Kestenbaum,et al. Growth Differentiation Factor-15 and Risk of CKD Progression. , 2017, Journal of the American Society of Nephrology : JASN.
[11] Marc P. Bonaca,et al. Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22 , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[12] Akshay S. Desai,et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.
[13] P. Ponikowski,et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.
[14] K. Unsicker,et al. The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. , 2013, Cytokine & growth factor reviews.
[15] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.
[16] Svati H Shah,et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. , 2015, JACC. Heart failure.
[17] Sohail Q Khan,et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. , 2009, European heart journal.
[18] F. Luft,et al. Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus , 2009, Hypertension.
[19] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[20] M. Frenneaux,et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy , 2009, European heart journal.
[21] A. Remppis,et al. Reference change values and determinants of variability of NT-proANP and GDF15 in stable chronic heart failure , 2009, Basic Research in Cardiology.
[22] R. Prager,et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes , 2016, Heart.
[23] P. Ponikowski,et al. Growth differentiation factor 15 (GDF‐15) in patients admitted for acute heart failure: results from the RELAX‐AHF study , 2015, European journal of heart failure.
[24] W. Kraus,et al. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. , 2017, JACC. Heart failure.
[25] W. Rottbauer,et al. Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study. , 2016, Clinical chemistry.
[26] H. White,et al. State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease. , 2017, Clinical chemistry.
[27] A. Jaffe,et al. Variability of biomarkers in patients with chronic heart failure and healthy controls , 2016, European journal of heart failure.
[28] T. Cash-Mason,et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates , 2017, Nature Medicine.